• Something wrong with this record ?

Antibodies Contributing to Focal Epilepsy Signs and Symptoms Score

MAAM. de Bruijn, AEM. Bastiaansen, H. Mojzisova, A. van Sonderen, RD. Thijs, MJM. Majoie, RPW. Rouhl, MH. van Coevorden-Hameete, JM. de Vries, A. Muñoz Lopetegi, B. Roozenbeek, MWJ. Schreurs, PAE. Sillevis Smitt, MJ. Titulaer, ACES Study Group

. 2021 ; 89 (4) : 698-710. [pub] 20210127

Language English Country United States

Document type Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21018887

OBJECTIVE: Diagnosing autoimmune encephalitis (AIE) is difficult in patients with less fulminant diseases such as epilepsy. However, recognition is important, as patients require immunotherapy. This study aims to identify antibodies in patients with focal epilepsy of unknown etiology, and to create a score to preselect patients requiring testing. METHODS: In this prospective, multicenter cohort study, adults with focal epilepsy of unknown etiology, without recognized AIE, were included, between December 2014 and December 2017, and followed for 1 year. Serum, and if available cerebrospinal fluid, were analyzed using different laboratory techniques. The ACES score was created using factors favoring an autoimmune etiology of seizures (AES), as determined by multivariate logistic regression. The model was externally validated and evaluated using the Concordance (C) statistic. RESULTS: We included 582 patients, with median epilepsy duration of 8 years (interquartile range = 2-18). Twenty patients (3.4%) had AES, of whom 3 had anti-leucine-rich glioma inactivated 1, 3 had anti-contactin-associated protein-like 2, 1 had anti-N-methyl-D-aspartate receptor, and 13 had anti-glutamic acid decarboxylase 65 (enzyme-linked immunosorbent assay concentrations >10,000IU/ml). Risk factors for AES were temporal magnetic resonance imaging hyperintensities (odds ratio [OR] = 255.3, 95% confidence interval [CI] = 19.6-3332.2, p < 0.0001), autoimmune diseases (OR = 13.31, 95% CI = 3.1-56.6, p = 0.0005), behavioral changes (OR 12.3, 95% CI = 3.2-49.9, p = 0.0003), autonomic symptoms (OR = 13.3, 95% CI = 3.1-56.6, p = 0.0005), cognitive symptoms (OR = 30.6, 95% CI = 2.4-382.7, p = 0.009), and speech problems (OR = 9.6, 95% CI = 2.0-46.7, p = 0.005). The internally validated C statistic was 0.95, and 0.92 in the validation cohort (n = 128). Assigning each factor 1 point, an antibodies contributing to focal epilepsy signs and symptoms (ACES) score ≥ 2 had a sensitivity of 100% to detect AES, and a specificity of 84.9%. INTERPRETATION: Specific signs point toward AES in focal epilepsy of unknown etiology. The ACES score (cutoff ≥ 2) is useful to select patients requiring antibody testing. ANN NEUROL 2021;89:698-710.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018887
003      
CZ-PrNML
005      
20210830100453.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ana.26013 $2 doi
035    __
$a (PubMed)33427313
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a de Bruijn, Marienke A A M $u Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
245    10
$a Antibodies Contributing to Focal Epilepsy Signs and Symptoms Score / $c MAAM. de Bruijn, AEM. Bastiaansen, H. Mojzisova, A. van Sonderen, RD. Thijs, MJM. Majoie, RPW. Rouhl, MH. van Coevorden-Hameete, JM. de Vries, A. Muñoz Lopetegi, B. Roozenbeek, MWJ. Schreurs, PAE. Sillevis Smitt, MJ. Titulaer, ACES Study Group
520    9_
$a OBJECTIVE: Diagnosing autoimmune encephalitis (AIE) is difficult in patients with less fulminant diseases such as epilepsy. However, recognition is important, as patients require immunotherapy. This study aims to identify antibodies in patients with focal epilepsy of unknown etiology, and to create a score to preselect patients requiring testing. METHODS: In this prospective, multicenter cohort study, adults with focal epilepsy of unknown etiology, without recognized AIE, were included, between December 2014 and December 2017, and followed for 1 year. Serum, and if available cerebrospinal fluid, were analyzed using different laboratory techniques. The ACES score was created using factors favoring an autoimmune etiology of seizures (AES), as determined by multivariate logistic regression. The model was externally validated and evaluated using the Concordance (C) statistic. RESULTS: We included 582 patients, with median epilepsy duration of 8 years (interquartile range = 2-18). Twenty patients (3.4%) had AES, of whom 3 had anti-leucine-rich glioma inactivated 1, 3 had anti-contactin-associated protein-like 2, 1 had anti-N-methyl-D-aspartate receptor, and 13 had anti-glutamic acid decarboxylase 65 (enzyme-linked immunosorbent assay concentrations >10,000IU/ml). Risk factors for AES were temporal magnetic resonance imaging hyperintensities (odds ratio [OR] = 255.3, 95% confidence interval [CI] = 19.6-3332.2, p < 0.0001), autoimmune diseases (OR = 13.31, 95% CI = 3.1-56.6, p = 0.0005), behavioral changes (OR 12.3, 95% CI = 3.2-49.9, p = 0.0003), autonomic symptoms (OR = 13.3, 95% CI = 3.1-56.6, p = 0.0005), cognitive symptoms (OR = 30.6, 95% CI = 2.4-382.7, p = 0.009), and speech problems (OR = 9.6, 95% CI = 2.0-46.7, p = 0.005). The internally validated C statistic was 0.95, and 0.92 in the validation cohort (n = 128). Assigning each factor 1 point, an antibodies contributing to focal epilepsy signs and symptoms (ACES) score ≥ 2 had a sensitivity of 100% to detect AES, and a specificity of 84.9%. INTERPRETATION: Specific signs point toward AES in focal epilepsy of unknown etiology. The ACES score (cutoff ≥ 2) is useful to select patients requiring antibody testing. ANN NEUROL 2021;89:698-710.
650    _2
$a dospělí $7 D000328
650    _2
$a autoprotilátky $x analýza $7 D001323
650    _2
$a autoimunitní nemoci $x diagnostické zobrazování $x imunologie $x psychologie $7 D001327
650    _2
$a chování $7 D001519
650    _2
$a kognitivní poruchy $x etiologie $x psychologie $7 D003072
650    _2
$a kohortové studie $7 D015331
650    _2
$a elektroencefalografie $7 D004569
650    _2
$a epilepsie parciální $x diagnostické zobrazování $x imunologie $x psychologie $7 D004828
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glutamát dekarboxyláza $x genetika $x imunologie $7 D005968
650    _2
$a lidé $7 D006801
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prospektivní studie $7 D011446
650    _2
$a rizikové faktory $7 D012307
650    _2
$a záchvaty $x diagnostické zobrazování $x etiologie $x imunologie $7 D012640
651    _2
$a Česká republika $7 D018153
651    _2
$a Nizozemsko $7 D009426
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bastiaansen, Anna E M $u Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
700    1_
$a Mojzisova, Hana $u Department of Neurology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic
700    1_
$a van Sonderen, Agnes $u Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
700    1_
$a Thijs, Roland D $u Department of Neurology, Stichting Epilepsie Instellingen Nederland, Heemstede, the Netherlands $u Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands
700    1_
$a Majoie, Marian J M $u Department of Neurology, Academic Center for Epileptology, Epilepsy Center Kempenhaeghe, Heeze, the Netherlands $u Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands $u Faculty of Health, Medicine, and Life Sciences, School of Health Professions Education, Maastricht University, Maastricht, the Netherlands $u Department of Neurology, Maastricht University Medical Center+, Maastricht, the Netherlands
700    1_
$a Rouhl, Rob P W $u Department of Neurology, Maastricht University Medical Center+, Maastricht, the Netherlands
700    1_
$a van Coevorden-Hameete, Marleen H $u Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
700    1_
$a de Vries, Juna M $u Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
700    1_
$a Muñoz Lopetegi, Amaia $u August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
700    1_
$a Roozenbeek, Bob $u Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
700    1_
$a Schreurs, Marco W J $u Department of Immunology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
700    1_
$a Sillevis Smitt, Peter A E $u Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
700    1_
$a Titulaer, Maarten J $u Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
710    2_
$a ACES Study Group
773    0_
$w MED00000428 $t Annals of neurology $x 1531-8249 $g Roč. 89, č. 4 (2021), s. 698-710
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33427313 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100453 $b ABA008
999    __
$a ok $b bmc $g 1689851 $s 1139333
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 89 $c 4 $d 698-710 $e 20210127 $i 1531-8249 $m Annals of neurology $n Ann Neurol $x MED00000428
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options